Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph L Pater

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17Hyman B Muss, Dongsheng Tu, James N Ingle, et al.
Circulation|April 2, 2008
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysisScott D Solomon, Janet Wittes, Peter V Finn, et al.
The New England Journal of Medicine|October 11, 2003
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancerPaul E Goss, James N Ingle, Silvana Martino, et al.
Journal of the National Cancer Institute|September 8, 2005
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17Paul E Goss, James N Ingle, Silvana Martino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifenPaul E Goss, James N Ingle, Joseph L Pater, et al.
Breast Cancer Research and Treatment|March 17, 2006
Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trialJames N Ingle, Dongsheng Tu, Joseph L Pater, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2007
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17Paul E Goss, James N Ingle, Silvana Martino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 9, 2014
Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancerElizabeth Maunsell, Paul E Goss, Rowan T Chlebowski, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17Hyman B Muss, Dongsheng Tu, James N Ingle, et al.
Circulation|April 2, 2008
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysisScott D Solomon, Janet Wittes, Peter V Finn, et al.
The New England Journal of Medicine|October 11, 2003
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancerPaul E Goss, James N Ingle, Silvana Martino, et al.
Journal of the National Cancer Institute|September 8, 2005
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17Paul E Goss, James N Ingle, Silvana Martino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifenPaul E Goss, James N Ingle, Joseph L Pater, et al.
Breast Cancer Research and Treatment|March 17, 2006
Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trialJames N Ingle, Dongsheng Tu, Joseph L Pater, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2007
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17Paul E Goss, James N Ingle, Silvana Martino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 9, 2014
Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancerElizabeth Maunsell, Paul E Goss, Rowan T Chlebowski, et al.
Pageof 3